4.8 Article

In Vivo RNAi Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling

Journal

CANCER CELL
Volume 24, Issue 1, Pages 45-58

Publisher

CELL PRESS
DOI: 10.1016/j.ccr.2013.05.004

Keywords

-

Funding

  1. GlaxoSmithKline
  2. Harvard Stem Cell Institute
  3. NIH [P01 CA108631, RC1 CA145229, R01 CA140292, CA148180]
  4. Leukemia and Lymphoma Society
  5. Medical Scientist Training Program from the National Institute of General Medical Sciences [T32GM007753]

Ask authors/readers for more resources

We used an in vivo small hairpin RNA (shRNA) screening approach to identify genes that are essential for MLL-AF9 acute myeloid leukemia (AML). We found that lntegrin Beta 3 (Itgb3) is essential for murine leukemia cells in vivo and for human leukemia cells in xenotransplantation studies. In leukemia cells, Itgb3 knockdown impaired homing, downregulated LSC transcriptional programs, and induced differentiation via the intracellular kinase Syk. In contrast, loss of Itgb3 in normal hematopoietic stem and progenitor cells did not affect engraftment, reconstitution, or differentiation. Finally, using an Itgb3 knockout mouse model, we confirmed that Itgb3 is dispensable for normal hematopoiesis but is required for leukemogenesis. Our results establish the significance of the Itgb3 signaling pathway as a potential therapeutic target in AML.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available